Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited operates in Biotechnology, part of the Healthcare sector. It booked ₹215 cr of revenue in its latest quarter (Q2 FY27) and kept 22.5% of sales as profit.
“is to become a leading, respected ` million and preferred enzymes and probiotics-based solutions R&D investment Customers across Your Company’s B2B foundation remains provider in the global market.”
Healthier than 75% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 80–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 53
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in ADVENZYMES?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 2%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹215 cr |
| Other Income | ₹9 cr |
| Total Income | ₹223 cr |
| Cost of Materials | ₹59 cr |
| Purchases of Stock-in-Trade | ₹1.2 L |
| Inventory Change (±) | ₹-3 cr |
| Employee Benefit Expense | ₹40 cr |
| Finance Costs | ₹1 cr |
| Depreciation & Amortisation | ₹11 cr |
| Other Expenses | ₹46 cr |
| Total Expenses | ₹154 cr |
| Profit before Tax | ₹69 cr |
| Tax Expense | ₹18 cr |
| Share of JV / Associates | ₹-1.8 L |
| Net Profit | ₹51 cr |
| Net margin on total income | 22.9% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 203 cr | 190 cr | 215 cr |
| Total income | 211 cr | 203 cr | 223 cr |
| Expenses | 151 cr | 149 cr | 154 cr |
| Profit before tax | 60 cr | 54 cr | 69 cr |
| Tax | 15 cr | 15 cr | 18 cr |
| Net profit (owners' share) | 43 cr | 37 cr | 48 cr |
| Net margin (owners' share, on revenue) | 21.1% | 19.5% | 22.5% |
| EPS (₹) | 3.84 | 3.31 | 4.33 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,770 | ₹4.25 L cr | 53.3 | 8.9% | 12.3% | — |
| Divi's Laboratories Limited | ₹10,064 | ₹2.67 L cr | 74.1 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,650 | ₹1.77 L cr | 82.7 | 11.6% | 10.7% | — |
| Laurus Labs Limited | ₹2,323 | ₹1.26 L cr | 71.1 | 29.1% | 20.0% | — |
| Zydus Lifesciences Limited | ₹1,241 | ₹1.24 L cr | 33.2 | 13.9% | 11.7% | — |
| Apollo Hospitals Enterprise Limited | ₹8,440 | ₹1.21 L cr | 52.2 | 24.5% | 8.2% | — |
| Dr. Reddy's Laboratories Limited | ₹1,368 | ₹1.14 L cr | 30.8 | 9.5% | 10.6% | — |
| Cipla Limited | ₹1,397 | ₹1.13 L cr | 32.2 | 9.9% | 11.9% | — |
| Mankind Pharma Limited | ₹2,475 | ₹1.02 L cr | 35.9 | 16.2% | 16.4% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹1.35 / share | 24 Jul 2026 |
| Dividend | ₹1.2 / share | 23 Jul 2025 |
| Dividend | ₹4 / share | 16 May 2025 |
| Dividend | ₹1.1 / share | 18 Jul 2024 |
| Dividend | ₹4 / share | 17 May 2024 |
| Dividend | ₹1 / share | 4 Aug 2023 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 15 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.